First Mercantile Trust’s Aclaris Therapeutics ACRS Stock Holding History

First Mercantile Trust’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$80K	Sell	4,433 -279	-6%	-$4.47K	0.01%	714
2021 Q2	$83K	Buy	+4,712	New	+$107K	0.01%	730
2017 Q2	–	Sell	-5,945	Closed	-$177K	–	811
2017 Q1	$177K	Buy	5,945 +600	+11%	+$17.3K	0.03%	604
2016 Q4	$145K	Buy	+5,345	New	+$136K	0.02%	663

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

First Mercantile Trust's ACRS Position: Q3 2021 in Review

First Mercantile Trust reduced its Aclaris Therapeutics (ACRS) stake by 5.9% in Q3 2021, selling an estimated $4.47K and leaving 4,433 shares worth $80K. The position accounts for 0.01% of the portfolio, ranked #714.

First Mercantile Trust first reported a position in ACRS in Q4 2016 and has held it in 4 quarters since. The position peaked at $177K in Q1 2017. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

First Mercantile Trust held 4,433 shares of Aclaris Therapeutics worth $80K as of Q3 2021.
First Mercantile Trust sold 279 Aclaris Therapeutics shares in Q3 2021, an estimated $4.47K.
Aclaris Therapeutics made up 0.01% of First Mercantile Trust's portfolio in Q3 2021, its #714 holding.
First Mercantile Trust first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 4 quarters since.
First Mercantile Trust's Aclaris Therapeutics position peaked at $177K in Q1 2017.
126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on First Mercantile Trust's 13F filing for Q3 2021, filed 24 Nov 2021.